Acme United Expects Profit Recovery Following Tariff-Related Cost Surge

Acme United Corporation (US: ACU – $41.61) reported that net sales for the quarter ended March 31, 2026 were $52.3 million compared to $46.0 million for the quarter ended March 31, 2025, an increase of 14%.

Despite the increase in sales, net income fell to $1.0 million, or $0.24 per diluted share, compared to $1.7 million, or $0.41 per diluted share, in the prior-year quarter. The decline—40% in net income and 41% in earnings per share—was primarily attributed to higher costs of sales and increased operating expenses.

A key factor behind the margin pressure was the impact of tariffs imposed in 2025. These higher costs were embedded in inventory and began affecting earnings as those goods were sold during the first quarter of 2026. The seasonal nature of the business, which typically sees lower sales in the first quarter, further amplified the effect of these increased costs.

Looking ahead, management indicated that the financial impact of tariffs was expected to gradually diminish over the next several quarters, as tariff rates had already begun to decline in late 2025 and early 2026. Additionally, the Company expects to work through higher-cost inventory during the second quarter, with a return to more normalized cost structures anticipated by the third quarter.

Importantly, the investments made in quality assurance at the Med-Nap facility are not expected to recur, which should provide some relief to operating expenses in upcoming quarters. At the same time, ongoing integration efforts related to My Medic and other acquisitions are expected to yield efficiencies, including cost savings through procurement synergies, streamlined operations, and reduced overhead.

Overall, while first-quarter earnings reflected near-term pressures, the Company’s performance highlighted continued demand for its products, successful execution of its acquisition strategy, and a commitment to strengthening its operational capabilities. Management expressed confidence that these initiatives, combined with easing cost headwinds, support improved profitability and sustained growth over the remainder of 2026.

We reiterate our buy recommendation for Acme United Corp. with a price target of $53.47 for 2026, which is 23% above today’s stock price.

Smallcaps.us Advice: Buy	Price Target: $52.60	Latest Company Report (pdf)
For important disclosures, please read our disclaimer.